Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.

Umamaheswar DuvvuriJonathan GeorgeSeungwon KimDiego AlvaradoVeronique M NeumeisterAhmed ChennaRichard GedrichThomas HawthorneTheresa LaValleeJennifer R GrandisJulie E Bauman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This study demonstrates that CDX-3379 can inhibit tumor ErbB3 phosphorylation in HNSCC. CDX-3379 was well tolerated and associated with measurable tumor regression. A phase II study (NCT03254927) has been initiated to evaluate CDX-3379 in combination with cetuximab for patients with advanced HNSCC.

Keyphrases

phase ii study
monoclonal antibody
end stage renal disease
locally advanced
newly diagnosed
chronic kidney disease
ejection fraction
tyrosine kinase
peritoneal dialysis
prognostic factors
clinical trial
randomized controlled trial
radiation therapy
squamous cell carcinoma
patient reported outcomes